The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Why Rheumatologists Should Ask Patients About Drug Use

Why Rheumatologists Should Ask Patients About Drug Use

September 8, 2016 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF
megaflopp/shutterstock.com

megaflopp/shutterstock.com

SAN FRANCISCO—“We’ve known for a long time that prescription medications and illicit drugs can both mimic and actually induce the autoimmune syndromes treated by rheumatologists,” Jonathan Graf, MD, professor of medicine at the University of California–San Francisco in the Division of Rheumatology at Zuckerberg San Francisco General Hospital (SFGH), said at the California Rheumatology Alliance 2016 Scientific & Medical Meeting in May.

You Might Also Like
  • Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges
  • Dual-Trained Rheumatologists Take Multidisciplinary Approach to Their Patients
  • Scleritis Often Diagnosed by Ophthalmologists, But Rheumatologists Help Determine Systemic Causes
Explore This Issue
September 2016
Also By This Author
  • Some Telemedicine Barriers Are Down During COVID-19 Pandemic

“There are syndromes associated with drug use that look like their non-drug counterparts, but with particular calling-card features,” Dr. Graf explained in a follow-up interview with The Rheumatologist. The worst of these is vasculitis. “It’s important for rheumatologists to have a generalized understanding of the drugs their patients may take, legal or not, that [have an] impact on autoimmune diseases. For many of these syndromes, you have an obvious treatment—get the patient to stop taking the drug and the condition may abate.” Unfortunately, there is little evidence to support medical treatments for some of these drug-related syndromes, he said, although skin grafts, antibiotics and systemic corticosteroids have been tried.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Detective Work

In his presentation, Dr. Graf described some detective work done by the rheumatologists at SFGH on a sequence of eight patients admitted to the hospital in 2009, starting with a 46-year-old woman who presented with cyanosis in her lower extremities. These patients presented a distinct syndrome with a puzzling mix of clinical manifestations including necrotic retiform purpura on the face and ears, skin necrosis, vasculopathy, neutropenia and acute kidney injury, along with characteristic autoantibody profiles and other laboratory findings. “The syndrome we were seeing had features that were not classic vasculitis. We realized there was a common thread, which was cocaine use, but not the classic syndrome of that.”

After a thorough investigation, it turned out they all were using cocaine that had been adulterated with levamisole, an anti-parasitic agent used in veterinary medicine and once a treatment for rheumatoid arthritis until it was discontinued in 1990 due to side effects. An advisory from the federal Substance Abuse and Mental Health Services Administration around the same time reported that 70% of the cocaine tested in July 2009 by the Drug Enforcement Administration was positive for levamisole.1 Since then, levamisole adulteration has been on the rise, although the full extent of the syndrome is not fully appreciated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This relatively new phenomenon is just the tip of the iceberg when it comes to rheumatologic disorders secondary to drug use, Dr. Graf said. “We’ve been called in with patients to rule out vasculitis. I’m now getting called in to see every weird cocaine toxicity in the hospital.” The rheumatologist often sees disease patterns for which the cause is unknown—or else genetically linked. In cases where features associated with drug use are present, it would be good to do a work-up for drug use, including a thorough medication history and, in some cases, urine drug screening. “Ask your patients about their drug use.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Practice Management Tagged With: California Rheumatology Alliance 2016, Diagnosis, drug use, patient care, Rheumatic Disease, rheumatologistIssue: September 2016

You Might Also Like:
  • Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges
  • Dual-Trained Rheumatologists Take Multidisciplinary Approach to Their Patients
  • Scleritis Often Diagnosed by Ophthalmologists, But Rheumatologists Help Determine Systemic Causes
  • Can Genetic Information Change the Clinical Care of Rheumatology Patients?

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.